
|Videos|October 6, 2016
Immunotherapy Combinations Under Investigation in NSCLC
Author(s)Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD, discusses the immunotherapy combinations under investigation in NSCLC during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
3
Hypoxia Tracer Gets FDA Breakthrough Status in HPV+ Oropharyngeal Cancer
4
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
5
































